Understanding DHODH Inhibition
Therapeutic Mechanisms of Action of JBZ-001
On top of the expected nucleotide depletion-induced cell stress, our DHODH inhibitor, JBZ-001, displays multiple mechanisms of action, broadening its potential clinical applications, including:
Explore JBZ-001’s Therapeutic Effects:
Biological Effect
Increased Expression of CD38 Expression on Cancer Cells
JBZ-001 induces the upregulation of CD38 on the surface of acute myeloid leukemia (AML) cells. This increased expression enhances the cells’ susceptibility to CD38-targeting antibodies, such as Daratumumab and Isatuximab, which are designed to bind and eliminate CD38-positive cells.
Combination Therapy Potential
Potent Synergy with CD38-Targeting Therapies
We have strong preclinical evidence that shows, by increasing CD38 expression on AML cells, JBZ-001 significantly boosts the efficacy of CD38-targeting therapies. This synergistic effect offers a promising combination approach, potentially improving treatment outcomes for patients with AML and other CD38-expressing cancers. View our pipeline.
To learn more, explore our preclinical data > here.
To learn more, explore our preclinical data > here.